Synergistic Interactions of MmpL3 Inhibitors with Antitubercular Compounds In Vitro

@inproceedings{Li2017SynergisticIO,
  title={Synergistic Interactions of MmpL3 Inhibitors with Antitubercular Compounds In Vitro},
  author={Wei Li and Andrea S{\'a}nchez-Hidalgo and Victoria Jones and Vinicius Calado Nogueira de Moura and E Jeffrey North and Mary Jackson},
  booktitle={Antimicrobial agents and chemotherapy},
  year={2017}
}
A number of inhibitors of the essential Mycobacterium tuberculosis mycolic acid transporter, MmpL3, are currently under development as potential novel antituberculosis agents. Using the checkerboard method to study the interaction profiles of various antituberculosis drugs or experimental compounds with two different chemotypes inhibiting this transporter (indolcarboxamides and adamantyl ureas), we showed that MmpL3 inhibitors act synergistically with rifampin, bedaquiline, clofazimine, and… CONTINUE READING

Figures, Tables, and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 11 CITATIONS

Better living through chemistry: Addressing emerging antibiotic resistance

  • Experimental biology and medicine
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

Therapeutic potential of promiscuous targets in Mycobacterium tuberculosis.

  • Current opinion in pharmacology
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 18 REFERENCES

Antiinfectives targeting enzymes and the proton motive force.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2015

Bactericidal mode of action of bedaquiline.

  • The Journal of antimicrobial chemotherapy
  • 2015